June 30, 2006 -- Celgene won its long-anticipated approval of Revlimid for multiple myeloma; Cephalon received an approvable letter for Fentora, an oral drug aimed at breakthrough pain; Vertex will collaborate with Janssen Pharma to develop a hepatitis C protease inhibitor; New River Pharma filed to begin human testing of NRP409, a therapy for hypothyroidism; Merck said the CDC recommended that Gardasil, its vaccine against HPV, be given to women between 11 and 26; Aastrom finished enrolling patients in a Phase I/II trial of a stem cell product for bone fractures; and deCode asked for permission to begin a Phase I test of a heart attack medication. The Centient Biotech 200™ rose 34 points to 3647.31, an increase of .95%. More details...
